<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887457</url>
  </required_header>
  <id_info>
    <org_study_id>13_DOG06_172</org_study_id>
    <secondary_id>2013-002578-34</secondary_id>
    <nct_id>NCT01887457</nct_id>
  </id_info>
  <brief_title>Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy</brief_title>
  <acronym>PIVOTAL</acronym>
  <official_title>PIVOTAL: Pharmacological Individualisation of VOriconazole Therapy for AntifungaL Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brynn Chappell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial to determine whether giving a patient a tailored dose of voriconazole is safe&#xD;
      and effective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Invasive fungal infections are a major cause of morbidity and mortality in patients with&#xD;
      haematological malignancy and haematopoietic stem cell transplantation.&#xD;
&#xD;
      Voriconazole is routinely used as a first-line agent for the treatment of invasive&#xD;
      aspergillosis, invasive fusariosis and scedosporiosis. Voriconazole has extreme&#xD;
      pharmacokinetic variability. Adult patients with a trough concentration of &lt; 1 mg/L have a&#xD;
      lower probability of clinical response whereas patients with trough concentrations &gt; 6 mg/L a&#xD;
      higher probability of toxicity.&#xD;
&#xD;
      Therapeutic drug monitoring for dose adjustment is advocated but there are no algorithms that&#xD;
      enable voriconazole dosage to be reliably adjusted to achieve desired trough concentrations&#xD;
      in a timely and optimally precise manner.&#xD;
&#xD;
      Novel ways to deliver optimised antifungal therapy are urgently required and this trial will&#xD;
      evaluate whether giving a patients a tailored dose of voriconazole is safe and effective.&#xD;
&#xD;
      Plasma concentrations will be taken in real time and inputted in dose software that will&#xD;
      calculate an optimum dose for the required trough concentration of 1-3 mg/L.&#xD;
&#xD;
      The software has been developed using data from phase I and III trials of voriconazole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Transfer of management of study&#xD;
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose adjustment success</measure>
    <time_frame>Day 5 of treatment</time_frame>
    <description>Dose adjustment success will be evaluated by plasma trough concentration on day 5, successful dose adjustment is defined as a trough concentration of 1-3 mg/L of voriconazole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality of patients</measure>
    <time_frame>35 Day after starting treatment</time_frame>
    <description>To examine the mortality of patients receiving individualised voriconazole dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Day 5 of treatment and 35 day follow-up</time_frame>
    <description>To evaluate the adverse events that are attributable to voriconazole as assessed by CTCAE v4.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Immunocompromised Patient</condition>
  <condition>Aspergillosis</condition>
  <condition>Fusarium</condition>
  <arm_group>
    <arm_group_label>Voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VFEND</intervention_name>
    <description>voriconazole will be administered in iv form</description>
    <arm_group_label>Voriconazole</arm_group_label>
    <other_name>voriconazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any adult ≥18 years old&#xD;
&#xD;
          -  Patients where a new course of voriconazole is indicated for suspected or confirmed&#xD;
             invasive aspergillosis or other serious fungal infections that is deemed by the&#xD;
             treating physician to be susceptible to voriconazole&#xD;
&#xD;
          -  Patients must have venous access to permit the administration of voriconazole and&#xD;
             enable the procurement of multiple plasma samples to measure voriconazole&#xD;
             concentrations.&#xD;
&#xD;
          -  Estimated creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Able to give written informed consent&#xD;
&#xD;
          -  Considered fit to receive the trial treatment&#xD;
&#xD;
          -  Able to remain in the hospital for at least 5 days or until they complete their trial&#xD;
             treatment&#xD;
&#xD;
          -  Female patients must satisfy the investigator that they are not pregnant, or are not&#xD;
             of childbearing potential, or are using adequate contraception&#xD;
&#xD;
          -  Men must also use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an estimated creatinine clearance &lt; 50 mL/minute (this precludes the use&#xD;
             of intravenous voriconazole)&#xD;
&#xD;
          -  Patients receiving any form of renal replacement therapy i.e. haemodialysis or&#xD;
             haemofiltration&#xD;
&#xD;
          -  Patients with hepatic insufficiency&#xD;
&#xD;
          -  Female patients that are pregnant, breast feeding or planning pregnancy during the&#xD;
             study&#xD;
&#xD;
          -  Past history of intolerance to voriconazole&#xD;
&#xD;
          -  Age &lt;18&#xD;
&#xD;
          -  Evidence of a clinically relevant fungal isolate that is resistant to voriconazole&#xD;
&#xD;
          -  QT prolongation on ECG&#xD;
&#xD;
          -  Use of other medications that contraindicate the use of voriconazole&#xD;
&#xD;
          -  Patients receiving any other medications that are contraindicated with the use of&#xD;
             voriconazole i.e. terfenadine, long acting barbiturates, ergot alkaloids, etc. (Refer&#xD;
             to SMPC). Only patients on rifampicin, rifabutin, phenytoin, and carbamazepine would&#xD;
             have voriconazole precluded. Voriconazole influences with the pharmacokinetics of many&#xD;
             additional agents- (see SMPC)- most importantly anti-rejection compounds-&#xD;
             cyclosporine, tacrolimus]&#xD;
&#xD;
          -  Uncontrolled cardiac, respiratory or other disease or any serious medical or&#xD;
             psychiatric disorder that would preclude trial therapy or informed consent.&#xD;
&#xD;
          -  Hypersensitivity to Voriconazole, its excipients or other triazoles&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Hope</last_name>
    <role>Study Chair</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.christie.nhs.uk/</url>
    <description>Christie NHS website</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Christie NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Brynn Chappell</investigator_full_name>
    <investigator_title>Clinical Trials Project Manager</investigator_title>
  </responsible_party>
  <keyword>voriconazole</keyword>
  <keyword>VFEND</keyword>
  <keyword>individualised</keyword>
  <keyword>personalised</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

